Clinical trials: Cutaneous Squamous Cell Cancer

Squamous Cell Carcinoma

Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

• Active, not recruiting
• Age: 18 years and older
• Phase 2
• Injection or infusion
• Results posted

This phase II single-arm two-stage neoadjuvant study of pembrolizumab in patients with PD-1 naïve high-risk resectable cutaneous squamous cell carcinoma (cSCC) will be conducted over a 52-week period.

Trial name

NCT04808999

Testing

Pembrolizumab Injection

Where

United States

Volunteers

30 people

Sponsor

Diwakar Davar